C&Cure Co., Ltd., founded by Professor Min Jeong-jun of Chonnam National University College of Medicine, attracts 2 billion won in investment

On December 30, 2019 CNCure, founded by Professor Min Jeong-jun of Chonnam National University College of Medicine, reported the company has attracted an investment of 2 billion won from DT&Investment (Press release, CNCure, DEC 30, 2019, View Source [SID1234649028]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Founded in August of last year, C&Cure Co., Ltd.’s main business objectives are the development of anticancer drugs based on a bacterial platform and theranostics, which simultaneously conducts diagnosis and treatment.

C&Cure Co., Ltd. is planning to begin clinical trials of bacterial anticancer drugs and radioactive pharmaceuticals that can precisely attack various types of cancer, including colon cancer, melanoma, metastatic cancer, and lung cancer. It has been reported that professors from Chonnam National University College of Medicine and Chonnam National University Hwasun Hospital, who are key researchers in this regard, are participating as shareholders.

In 2017, Professor Min developed a genetically engineered fusion cancer treatment bacteria and announced in the international journal Science Translational Medicine that it could dramatically improve the effectiveness of cancer treatment through immunotherapy, which was selected as the online cover story.

At the time, an experiment on mice transplanted with various cancers caused a great stir in the academic world by showing a cancer cure rate of over 80% in just 23 days.

Professor Min Jeong-jun said, "For the past two years, we have been conducting continuous research to suppress side effects such as mutations using genetic engineering methods, and now that we have achieved a level of technological perfection that we are confident about in clinical practice, we have decided to start a business."

Meanwhile, Professor Min Jeong-jun is currently the Director of the Life Science Research Institute at Chonnam National University Hospital in Hwasun, Director of the Big Data Center for Five Major Cancers, Director of the Molecular Imaging Theranostics Research Institute at Chonnam National University, Director of the World Society of Molecular Imaging, and Director of the Asia Oceania Society of Nuclear Medicine, and is known as a global authority in the field of molecular imaging and theranostics.